Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Eli Lilly said Thursday it will delay filing for FDA approval of its next-gen weight-loss drug, retatrutide, until the first quarter.
Two more Phase 3 trials showed weight loss above 20%
Retatrutide delivered substantial weight loss in two additional late-stage trials.
Drugmaker Eli Lilly said Thursday that it is on track to seek federal approval for its next-generation obesity drug early next year. Lilly became the first drug company to reach a trillion dollar valuation last fall as sales of its weight loss drugs took off. Among adults with general obesity, the weekly injectable lowered the weight of late-stage trial participants by an average of 28% over 80 weeks at the highest doses tested.
Investing.com -- Eli Lilly announced Thursday it will file for approval of its next-generation obesity drug retatrutide in the first quarter of 2027, pushing back from an earlier timeline that targeted this year. The pharmaceutical company said it needs additional time to collect and verify manufacturing and quality-control data required by regulators.
In recent days, Novo Nordisk filed a federal lawsuit against Eli Lilly, alleging that Lilly’s nationwide advertising for obesity and diabetes drugs like Zepbound and Mounjaro used outdated clinical data and unfair dose comparisons to claim superiority over Novo’s Wegovy and Ozempic. The case raises legal and regulatory questions around drug marketing practices in the high-stakes GLP-1 market, where only a few companies currently compete at scale. Beyond the courtroom, this dispute highlights...
If approved, Lilly’s triple-g agonist would become the company’s fifth glucagon-based drug to be marketed.
LLY's blockbuster GLP-1 portfolio takes center stage as investors watch Mounjaro, Zepbound and Foundayo for clues to Q2 growth and outlook.
Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline.
Retatrutide, a once-weekly triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors, met the primary endpoint in both the Triumph-2 and Triumph-3 Phase 3 studies.
The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.
Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment delivered substantial results.
Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment delivered substantial results.
July 23 (Reuters) - India's Cipla reported a bigger-than-expected fall in first-quarter profit on Thursday, extending its run of declines on muted sales of a generic cancer drug and supply disruptions
Big Pharma is buying its way out of the patent cliff, while Novartis AG (NYSE:NVS) is trying to out-develop it. A Record Year for Biotech Deals The scale of that buying activity appears in this year’s deal totals. Biotech M&A has hit a record pace in 2026, with deal value reaching $216 billion so far […]
Novo Nordisk just sued Eli Lilly over weight-loss drug ads, but the moment the lawsuit hit, investors moved in exactly the wrong direction for Novo. Here is what the stock reaction reveals about who is actually winning this war.
Novo Nordisk sues LLY over high-profile ads promoting Zepbound and Mounjaro, arguing newer clinical data changes the comparison as the GLP-1 rivalry intensifies.
Eli Lilly's expanding GLP-1 portfolio and pipeline remain in focus as demand stays strong ahead of its second-quarter earnings results.
Nektar begins two phase III ZENITH AD studies of rezpeg for moderate-to-severe atopic dermatitis, with a third study set to start in September. Shares rise.
Eli Lilly will release its second-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.
Jim Cramer is sounding the alarm for investors still riding the AI wave, and his warning carries a specific body count. Here is where he says the smart money is quietly moving before the damage hits.
The Danish pharma giant alleged Lilly misled consumers with false advertising claims that its weight loss drug is superior to Novo’s.
Novo Nordisk’s lawsuit against Eli Lilly (LLY) over alleged misleading GLP-1 advertising has put fresh attention on Lilly’s stock and raised questions about how core obesity and diabetes franchises are being marketed. See our latest analysis for Eli Lilly. Against this legal backdrop, Eli Lilly’s 1-day share price return of 2.49% and 30-day share price return of 6.99% sit within a broader upswing, with a 52.46% 1-year total shareholder return and a very large 5-year total shareholder return...
Novo Nordisk stock has had a tough stretch over the past few years, yet current valuation checks suggest the market may now be pricing it more cautiously than the fundamentals imply. Over the past 3 years, Novo Nordisk has delivered a total shareholder return that is down 35.8%, which puts the recent share price in the context of a material drawdown for long term holders. Expectations around the obesity and diabetes franchise, including products such as Wegovy, sit alongside legal and...
Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.
The weight-loss drug wars reached a new level of intensity Tuesday as Novo Nordisk sued Eli Lilly , accusing its arch-rival of misleading advertising.
Eli Lilly's GLP-1 portfolio, pipeline progress and 2026 acquisitions are driving growth despite pricing pressure and rising competition.
Healthcare stocks advanced late Tuesday afternoon with the NYSE Healthcare Index rising 0.6% and the
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
